Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00052065 · ClinicalTrials.gov registry record · Phase 1
TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer
A Phase 1 study, sponsored by Telik.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT00052065 is a Phase 1 study that has completed, run by Telik. The registered enrollment target is 28 participants.
The verdict
NCT00052065, a Phase 1 study, has completed, sponsored by Telik.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This is a dose-ranging, open-label, Phase 1-2a study of TLK286 in combination with Doxil in patients with platinum refractory or resistant ovarian cancer.
Interventions
- DRUG TLK286
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2003-02 |
| Est. Completion | 2006-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00052065
The ClinicalTrials.gov registry entry for NCT00052065 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Telik, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TLK286 is the first listed.
NCT00052065 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00052065 about?
NCT00052065 is a clinical study titled "TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer". This is a dose-ranging, open-label, Phase 1-2a study of TLK286 in combination with Doxil in patients with platinum refractory or resistant ovarian cancer.
What is the current status of trial NCT00052065?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2003-02. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00052065?
The interventions under investigation include: TLK286 (DRUG).
Who is sponsoring clinical trial NCT00052065?
This trial is sponsored by Telik, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.